Akums drugs & pharma has filed its quarterly compliance certificate with stock exchanges for the quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory regulatory document to both the National Stock Exchange of India Limited and BSE Limited on April 4, 2026.

Regulatory Compliance Certificate

The certificate was issued pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. This regulation requires companies to confirm compliance with dematerialisation processes and related procedures on a quarterly basis.

Registrar Confirmation

The compliance certificate was provided by MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, which serves as the company's Registrar & Share Transfer Agent. The certificate was signed by Ashok Shetty, Sr. Vice President-Corporate Registry, and dated April 3, 2026.

The registrar confirmed that securities received from depository participants for dematerialisation during the quarter ended March 31, 2026, were properly processed. Key confirmations included:

• Securities received for dematerialisation were confirmed or rejected to depositories within prescribed timelines
• Security certificates received were mutilated and cancelled after due verification
• Names of depositories were substituted in the register of members as registered owners
• All securities comprised in the certificates have been listed on stock exchanges where earlier issued securities are listed

Company Information

Akums Drugs and Pharmaceuticals Limited operates from its registered office at 304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034. The company maintains its manufacturing facility at Plot No. 131 to 133, Block-C, Mangolpuri Industrial Area, Phase-I, Delhi-110083.

The filing represents routine quarterly compliance reporting required under SEBI regulations, ensuring transparency in the company's share transfer and dematerialisation processes.

Akums Drugs & Pharma conducted its Q3FY26 earnings conference call on February 16, 2026, revealing strong operational performance driven by robust CDMO growth and progress on international expansion initiatives.

Financial Performance Highlights

The company reported consolidated operating revenue of ₹1,160 crores for Q3FY26, marking a significant 14.8% year-on-year growth and 14% quarter-on-quarter improvement. Operating EBITDA reached ₹147 crores, up 21% year-on-year and 55.4% quarter-on-quarter, with margins improving to 12.7%.

CDMO Business Drives Growth

The CDMO segment emerged as the primary growth driver, generating revenue of ₹916 crores, up 16.3% year-on-year and 13.8% quarter-on-quarter. The segment benefited from double-digit volume growth across existing customers and therapeutic areas, despite continued API pricing pressures.

Segment-wise Performance Analysis

Domestic branded formulation revenue stood at ₹115 crores, growing 4.2% year-on-year with EBITDA of ₹25 crores, up 25.1% year-on-year. International branded formulation showed remarkable recovery with revenue of ₹50 crores, increasing 18% year-on-year and over 120% quarter-on-quarter.

The API business continued facing challenges with revenue of ₹54 crores but negative EBITDA of ₹7 crores, though losses reduced from ₹11 crores in Q3FY25. Trade generics revenue declined 18% year-on-year to ₹25 crores with EBITDA loss of ₹3 crores.

European Expansion Progress

Management highlighted significant progress on European operations. The company received EU GMP accreditation for its oral liquids facility Plant 2 in January 2026, following successful inspection in October 2025. Commercial supplies to Europe are expected to commence in FY28, with an annual revenue potential of EUR 35 million through December 2032.

Plant 1 also received renewal of EU GMP certification, with finished oral formulation supplies to Europe already commenced in the current fiscal.

Zambia Contract Update

The Zambia project remains on track with commercial supplies from Indian plants expected in H1 of calendar year 2026. The contract involves $25 million annual supplies for the first two years, with local facility construction planned to begin soon, taking approximately two years for completion.

Technology and Infrastructure Investments

The company initiated SAP S/4HANA transformation to improve efficiency and automation across operations. Additionally, Darwinbox implementation aims to enhance employee experience and automate HR functions. These technological upgrades support the company's future-ready organization strategy.

Cash Position and Outlook

Akums maintains a strong cash surplus of ₹1,573 crores with operating cash flow of ₹1,109.5 crores and free cash flow of ₹944.5 crores. Management indicated active evaluation of acquisition opportunities that complement existing business operations.

The company expects continued double-digit volume growth in Q4FY26, with management expressing confidence in sustaining current performance levels across key business segments.